Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michele Baccarani is active.

Publication


Featured researches published by Michele Baccarani.


British Journal of Haematology | 1991

mdr-1 GENE AMPLIFICATION IN ACUTE LYMPHOBLASTIC LEUKAEMIA PRIOR TO ANTILEUKAEMIC TREATMENT

Mariagrazia Michieli; Mauro Giacca; Renato Fanin; Daniela Damiani; Antonella Geromin; Michele Baccarani

Rovira. M.. Cervantes, F., Nomdeden. B. & Roman, C. (1990) Chronic neutrophilic leukaemia preceeding for seven years the development of multiple myeloma. Acta Haematologica. 83,94-95. Saglio, G.. Guerrasio. A.. Ross, C.. Zaccaria, A.. Tassinari, A.. Serra. A,. Rege-Cambrin. G.. Mama, U. & Gavosto. F. (1990) New type of kr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 76, 1819-1824. log.tj. 31, 300-301. Saglio, G., Ponzetto, C., Guerrasio. A.. Tassinari, A.. Zaccaria. A.. Testoni. P., Celso, B.. Rege Cambrin. G.. Serra. A.. Pegoraro. L.. Avanzi, G.C.. Attadia, V., Falda. M.. & Gavosto. F. (1988) Variability of the molecular defects corresponding to the presence of the Philadelphia chromosome in human hematologic malignancies. Blood. 72, 1203-1208. Yunis. 1.1. (1981)Newchromosome techniquein thestudy ofhuman neoplasia. Human Pathology. 12, 530-549.


Allergy & rhinology (Providence, R.I.) | 2011

Sinonasal risk factors for the development of invasive fungal sinusitis in hematological patients: Are they important?

Ignacio Javier Fernandez; Marta Stanzani; Giulia Tolomelli; Ernesto Pasquini; Nicola Vianelli; Michele Baccarani; Vittorio Sciarretta

Invasive fungal sinusitis (IFS) is a highly aggressive infection that can affect hematologic patients. The classically described general risk factors, however, do not fully explain the development of IFS in a small percentage of cases. This study examined the impact of anatomic sinonasal factors and environmental factors on the development of IFS in high-risk patients. Medical records and computed tomography (CT) scans of patients admitted to our institution who were at high risk of developing IFS were retrospectively reviewed. Twenty-seven patients of 797 fulfilled the inclusion criteria. Patients affected by IFS were compared with patients not affected to identify possible sinonasal and environmental risk factors of IFS. Seven patients were excluded because of the lack of adequate radiological images. Six of the 20 eligible patients were assigned to the study group of patients affected by IFS and the remaining 14 patients were assigned to the control group. All but one case developed the infection during the summer with a significantly higher mean environmental temperature (p = 0.002). Anatomic nasal alterations were found in all patients affected by IFS and were significantly more frequent than in the control group (p = 0.014). It would be advisable to have patients with hematologic risk factors of IFS, especially during the summer period, undergo endoscopic nasal assessment. Furthermore, a CT finding of anatomic nasal alterations, such as anterior nasal septum deviation causing nasal obstruction, should increase the suspicion of IFS in case of the occurrence of nasal symptoms.


Archive | 2016

Safety Profiles of First-Line TKIs and Managing Adverse Effects

Gianantonio Rosti; Fausto Castagnetti; Gabriele Gugliotta; Michele Baccarani

The treatment armamentarium of chronic myeloid leukemia (CML) is based on at least five TKIs, employed either in first-line CP (imatinib, dasatinib, and nilotinib) and in second and third line (dasatinib, nilotinib, bosutinib, and ponatinib). These drugs share the same target of interest (BCR-ABL) but have profound different off-target effects. In turn, the general spectrum of adverse events experienced by the treated patients, either clinical symptoms, biochemical abnormalities, or severe AEs (or “complications”), varies considerably. SAEs are more frequent with second- and third-generation TKIs, and from this point of view, imatinib remains the safest drug. The early identification of CML patient candidates to experience more frequently SAEs with second (and third)-generation TKIs is of course part of the treatment decision process where the right balance between risk and benefit should be accomplished. Second-generation TKIs, nilotinib and dasatinib, are considered generally to be better tolerated than imatinib. However, two types of complications are described more frequently with nilotinib and ponatinib (cardiovascular, in general, and PAOD in particular) and with dasatinib (pleural effusions and pulmonary hypertension) if compared with imatinib. These two types of complications deserve a particular attention.


Aging (Albany NY) | 2011

Imatinib in chronic myeloid leukemia elderly patients

Gabriele Gugliotta; Fausto Castagnetti; Francesca Palandri; Michele Baccarani; Gianantonio Rosti


Archive | 2008

Rituximab therapy in adult patients with relapsed or refractory ITP: long term follow-up results

Marta Medeot; Francesco Zaja; Nicola Vianelli; Marta Lisa Battista; Michele Baccarani; Franca Soldano; Miriam Isola; Stefano De Luca; Renato Fanin; L Medica; A. Seragnoli


Archive | 2013

Working Party on CML analysis adverse prognostic influence on frontline imatinib therapy: a GIMEMA Additional chromosomal abnormalities in Philadelphia-positive clone:

Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani; Nicoletta Testoni; Paolo Bernasconi; Francesca Palandri; Fabrizio Pane; Alfonso Zaccaria; Maria Grazia Grimoldi; Alessandro Gozzetti; Gaia Ameli; Giorgina Specchia; Lucia Zanatta; Marco Mancini; Simona Luatti; Fausto Castagnetti; Giulia Marzocchi; Carmen Baldazzi; Gabriele Gugliotta


Archive | 2017

Prognostic Discrimination in "GoodRisk" Chronic Granulocytic Leukemia

Joseph E. Sokal; Edwin B. Cox; Michele Baccarani; Sante Tuna; German A. Gomez; Judith E. Robertson; C. Y. Tso; Thomas J. Braun; Bayard D. Clarkson; Francisco Cervantes


Archive | 2014

WHERE SCIENCE MEETS CLINICAL PRACTICE

Michele Baccarani; R. Hehlmann; Francisco Cervantes; Francois Guilhot; Wolf-Karsten Hofmann; Gert J. Ossenkoppele


The Treatment of Chronic Myeloid Leukemia | 2013

Diagnosis and classification of the risk

Gabriele Gugliotta; Fausto Castagnetti; Francesca Palandri; Michele Baccarani; Gianantonio Rosti


Archive | 2013

responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon-

Giovanni Martinelli; Sante Tura; Michele Baccarani; Enrico Montefusco; Giuliana Alimena; Joerg Hasford; Sue Richards; Giuseppe Saglio; Nicoletta Testoni; Josef Thaler; Bengt Simonsson; Andries Louwagie; Josy Reiffers; Francois Xavier Mahon; R. Hehlmann; Andreas Hochhaus; Patricia Shepherd; Juan Luis Steegmann; Gianantonio Rosti; Francois Guilhot; Joelle Guilhot; Elena Trabacchi

Collaboration


Dive into the Michele Baccarani's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giovanni Martinelli

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Nicoletta Testoni

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fabrizio Pane

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge